ライフサイエンスコーパス: nitrofurantoin

1 illin-sulbactam, cefoxitin, minocycline, and nitrofurantoin).

2 e, moxifloxacin, cephalexin, diclofenac, and nitrofurantoin.

3 Both episodes responded to treatment with nitrofurantoin.

4 not to menadione, plumbagin, pyrogallol, or nitrofurantoin.

5 ased sensitivity to killing by bleomycin and nitrofurantoin.

6 No elevated risk was observed for nitrofurantoin.

7 cin (1500 mg twice daily for 5 days) or oral nitrofurantoin (100 mg twice daily for 5 days), with ran

8 ixime (400 mg once daily for 3 days) or oral nitrofurantoin (100 mg twice daily for 7 days).

9 1.2 (95% CI, 19.9-22.7) per 1000 infants for nitrofurantoin, 23.5 (95% CI, 18.8-28.9) per 1000 infant

10 or 60 DILI cases with latency >365 days were nitrofurantoin (25%) or minocycline (17%).

11 6%), azathioprine (4%), infliximab (4%), and nitrofurantoin (4%).

12 IQR) gestational age differed by antibiotic (nitrofurantoin, 62 [45-77] days; TMP-SMX, 26 [13-59] day

13 CI, 184-718), and 1 of 1369 patients taking nitrofurantoin (73 of 100,000; 95% CI, 20-187).

14 ES24 is equivalent to or better than that of nitrofurantoin, a known antibiotic that, although struct

15 id overdose was 1.09 (95% CI, 0.79-1.50) for nitrofurantoin and 0.94 (95% CI, 0.68-1.31) for fluoroqu

16 hogens causing acute cystitis, resistance to nitrofurantoin and ciprofloxacin remained infrequent.

17 ns exposed to ciprofloxacin, cycloserine, or nitrofurantoin and identify 812 resistance mutations, ma

18 oprim-sulfamethoxazole, fluoroquinolones, or nitrofurantoin, and assessed for extended-spectrum B-lac

19 n pharmaceuticals (nifuroxazide, nifurtimox, nitrofurantoin, and nitrofural), which were obtained wit

20 in, ampicillin, ciprofloxacin, levofloxacin, nitrofurantoin, and tetracycline.

21 Additional associations were evident with nitrofurantoin (aOR, 2.2; 95% CI, 2.1-2.4), penicillins

22 ciprofloxacin engendered 89% more risk than nitrofurantoin (ARR = 1.89, 95% CI: 1.45, 2.68), and cli

23 Chloramphenicol, furazolidone and nitrofurantoin (banned compounds in food items) were det

24 cribe the introduction of new ampicillin and nitrofurantoin breakpoints, updated MIC breakpoints for

25 ubstrates include numerous drugs (topotecan, nitrofurantoin, cimetidine) as well as food carcinogens

26 shed for penicillin, ampicillin, vancomycin, nitrofurantoin, ciprofloxacin, levofloxacin, and tetracy

27 rity of isolates (76.2%) were susceptible to nitrofurantoin, cotrimoxazole, and cefpodoxime.

28 s (ciprofloxacin, gentamicin, meropenem, and nitrofurantoin), each having a distinct mechanism of act

29 e, 30 [27-34] years) included 42 402 (59.2%) nitrofurantoin-exposed, 3494 (4.9%) TMP-SMX-exposed, 366

30 Nitrofurantoin, furazolidone, furaltadone and nitrofuraz

31 In contrast, the prevalence of resistance to nitrofurantoin, gentamicin, and ciprofloxacin hydrochlor

32 (767 in the gepotidacin group and 764 in the nitrofurantoin group in EAGLE-2, and 805 in the gepotida

33 805 in the gepotidacin group and 800 in the nitrofurantoin group in EAGLE-3).

34 cin and 135 (47.0%) of 287 patients assigned nitrofurantoin had therapeutic success (adjusted differe

35 cin and 115 (43.6%) of 264 patients assigned nitrofurantoin had therapeutic success (adjusted differe

36 and safety of oral gepotidacin with that of nitrofurantoin in adolescent and adult female individual

37 Gepotidacin was non-inferior to nitrofurantoin in both studies and superior to nitrofura

38 trofurantoin in both studies and superior to nitrofurantoin in EAGLE-3.

39 Treatment shifted mostly to first-line (eg, nitrofurantoin in uUTI, amoxicillin in AS, macrolides in

40 r high-level gentamicin resistance and 1 for nitrofurantoin, in E. faecium isolates.

41 istance to trimethoprim-sulfamethoxazole and nitrofurantoin, it was more susceptible to ampicillin th

42 in, ciprofloxacin, erythromycin, penicillin, nitrofurantoin, linezolid, quinupristin/dalfopristin, ty

43 This work investigates the use of nitrofurantoin loaded poly(lactic-co-glycolic acid) (PLG

44 Ampicillin and nitrofurantoin MIC breakpoints were established, and pen

45 oxazole (160/800 mg twice daily for 3 days), nitrofurantoin monohydrate/macrocrystals (100 mg twice d

46 ferent antibiotics, gentamicin, ceftazidime, nitrofurantoin, nalidixic acid, ofloxacin.

47 cer drug Flutamide (FLU) and antibiotic drug Nitrofurantoin (NF) was developed based on the glassy ca

48 or furaltadone (FTD), furazolidone (FZD) and nitrofurantoin (NFT).

49 -imidazolidinedione (AHD), the metabolite of Nitrofurantoin (NFT).

50 ly significant) to all antimicrobials except nitrofurantoin (NIT) were higher in independent faciliti

51 Compared with nitrofurantoin, non-first-line agents were associated wi

52 must also have been treated with first-line (nitrofurantoin or trimethoprim-sulfamethoxazole), fluoro

53 who initiated sulfamethoxazole/trimethoprim, nitrofurantoin, or fluoroquinolone therapy.

54 therapy with trimethoprim-sulfamethoxazole, nitrofurantoin, or fosfomycin is indicated for acute cys

55 In the 3 UTIs/year model, nitrofurantoin prophylaxis was most effective, reducing

56 ical trials published: (1) daily antibiotic (nitrofurantoin) prophylaxis; (2) daily estrogen prophyla

57 ibiotics (beta-lactam, imidazole, macrolide, nitrofurantoin, quinolone, sulphonamide and trimethoprim

58 tible to ceftaroline, daptomycin, linezolid, nitrofurantoin, quinupristin-dalfopristin, rifampin, tig

59 e literature, the activity of fosfomycin and nitrofurantoin remain high for most cases of MDR Escheri

60 RR, 1.35; 95% CI, 1.04-1.75) but similar for nitrofurantoin (RR, 1.12; 95% CI, 1.00-1.26) and fluoroq

61 Nitrofurantoin showed >80% susceptibility in all groups.

62 evaluated in randomly assigned patients with nitrofurantoin-susceptible qualifying uropathogens (>=10

63 Gentamicin- and nitrofurantoin-treated sensitive strains showed an incre

64 st-trimester antibiotic prescription fill of nitrofurantoin, trimethoprim-sulfamethoxazole (TMP-SMX),

65 solates at high risk of nonsusceptibility to nitrofurantoin, trimethoprim-sulfamethoxazole, beta-lact

66 following antibiotics as first-line therapy: nitrofurantoin, trimethoprim-sulfamethoxazole, fosfomyci

67 c antibiotic and any urinary antibiotic (eg, nitrofurantoin, trimethoprim/sulfonamides, ciprofloxacin

68 prim-sulfamethoxazole, fluoroquinolones, and nitrofurantoin was 25.4%, 21.1%, and 3.8%, respectively.

69 , whereas the most common adverse event with nitrofurantoin was nausea (in 29 [4%] of 760 patients in

70 ne agents, trimethoprim-sulfamethoxazole (vs nitrofurantoin) was associated with higher risk of sever

71 For two antibiotics (rifampicin and nitrofurantoin), we found that sub-populations were able

72 Like nitrofurantoin, we find that ES24 requires activation by

73 ural modifications of the antibacterial drug nitrofurantoin were envisioned, employing drug repurposi